Medical Device DTC Advertising: Rules and Digital Tactics
How medical device DTC advertising differs from drug ads: FDA and FTC roles, restricted devices, claims, digital tactics, and measurement.
The short answer
Medical device DTC advertising follows different rules from prescription drug advertising. FDA oversees advertising for restricted devices, while the FTC oversees advertising for most other devices, under truth-in-advertising rules. Digital tactics are similar to DTC pharma: search, social, CTV, programmatic, and condition content, but the patient path often runs through a procedure, a specialist referral, or a direct purchase, so measurement and targeting must follow that path.
Device marketers often borrow DTC pharma playbooks. Many tactics transfer. The rules and the patient path often do not.
Who regulates what
| Product | Advertising oversight | Notes |
|---|---|---|
| Prescription drugs | FDA | Fair balance, brief summary or major statement |
| Restricted devices | FDA | Brief statement of intended uses and relevant warnings |
| Most other devices | FTC | Truthful, not misleading, substantiated claims |
| OTC drugs | FTC for advertising, FDA for labeling | See OTC vs. Rx DTC |
Promotional materials can also be treated as labeling, which FDA regulates. Device teams should confirm the classification with regulatory counsel.
How the patient path differs
Device patient journeys vary:
- Implant or procedure. Patient researches, sees a specialist, may need imaging or tests, then a procedure. Long consideration.
- Prescribed device. Patient and HCP decide; supplier dispenses (for example, continuous glucose monitors).
- Direct purchase. Consumer buys directly (some hearing aids, monitors).
Each path needs different calls to action and measurement.
Digital tactics
- Search for symptom and treatment queries. Health ad policies on platforms apply.
- Condition content to explain options, including procedures.
- Physician finder tools to connect patients with trained specialists.
- CTV and online video for awareness, especially for procedure-based devices. See healthcare video strategy.
- Social for education and patient stories, with disclosure and moderation rules.
- Programmatic with privacy-safe targeting. See programmatic for medical device marketing.
Claims and evidence
- Claims must match cleared or approved indications for regulated devices.
- Outcome claims need evidence.
- Patient testimonials must reflect typical results or be clearly qualified, under FTC endorsement guidance.
Measurement
| Path | Useful measures |
|---|---|
| Procedure | Physician finder use, appointment requests, procedure volume at trained centers (aggregated) |
| Prescribed device | HCP conversations, prescriptions or orders, starts |
| Direct purchase | Site visits, purchases, returns |
Use privacy-safe, aggregated methods for any health outcomes. The DTC KPI ladder applies with adjustments.
Common mistakes
- Assuming drug fair balance rules apply exactly, or not at all, without checking classification.
- Using testimonials that suggest atypical results.
- Measuring only clicks for a journey that ends months later in a procedure.
Practical takeaway
Before planning device DTC media, confirm with regulatory counsel whether the device is restricted and which rules apply, then map the patient path from first search to procedure or purchase. Choose KPIs for each step of that path, not just the first one.
Frequently asked questions
Who regulates medical device advertising?
FDA regulates advertising for restricted devices; the FTC regulates advertising for most other devices. FDA also regulates device labeling, and promotional materials can count as labeling.
What is a restricted device?
A device FDA has restricted to sale, distribution, or use on the order of a licensed practitioner or under other conditions. Its advertising must meet FDA requirements.
Can device ads make comparative claims?
Claims must be truthful, not misleading, and backed by appropriate evidence. Comparative claims need strong substantiation.
Sources
- FDA, Overview of Device Regulation
- FTC, Health Products Compliance Guidance
- eCFR, 21 CFR Part 801, Labeling
- Google Ads policy, Healthcare and medicines
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.